XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity
6 Months Ended
Oct. 25, 2024
Share-Based Payment Arrangement [Abstract]  
Stockholders' Equity

8. Stockholders’ Equity

Restricted Stock Units

We granted approximately 3 million restricted stock units (RSUs), including performance-based RSUs (PBRSUs), with a weighted average grant date fair value of $127.61 per share during the six months ended October 25, 2024.

In the six months ended October 25, 2024, we granted PBRSUs to certain of our executives. Each PBRSU has performance-based vesting criteria (in addition to the service-based vesting criteria) such that the PBRSUs cliff-vest at the end of a three year performance period, which began on the date specified in the grant agreements and typically ends on the last day of the third fiscal year, following the grant date. The number of shares that will be used to calculate the settlement amount for all of these PBRSUs at the end of the applicable performance and service period will range from 0% to 200% of a target number of shares originally granted. For half of the PBRSUs granted in the six months ended October 25, 2024, the number of shares used to calculate the settlement amount will depend upon our Total Stockholder Return (TSR) as compared to the TSR of a specified group of benchmark peer companies (each expressed as a growth rate percentage) calculated as of the end of the performance period. For the remaining half of the PBRSUs granted in the six months ended October 25, 2024, the number of shares used to calculate the settlement amount will depend upon the Company's billings result average over the three-year performance period. The billings result average is computed based on achievement against annual billings targets, with each target set at the beginning of the respective fiscal year, during the

three-year performance period. Billings for purposes of measuring the performance of these PBRSUs means the total obtained by adding net revenues as reported on the Company's Consolidated Statements of Income to the amount reported as the change in deferred revenue and financed unearned services revenue on the Consolidated Statements of Cash Flows for the applicable measurement period, excluding the impact of fluctuations in foreign currency exchange rates. The aggregate grant date fair value of PBRSUs granted in the current year was $62 million, which is being recognized to compensation expense over the remaining performance / service periods.

Stock-Based Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of income as follows (in millions):

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

October 25,
 2024

 

 

October 27,
2023

 

 

October 25,
 2024

 

 

October 27,
2023

 

Cost of product revenues

 

$

2

 

 

$

1

 

 

$

3

 

 

$

2

 

Cost of services revenues

 

 

6

 

 

 

6

 

 

 

12

 

 

 

12

 

Sales and marketing

 

 

43

 

 

 

37

 

 

 

78

 

 

 

73

 

Research and development

 

 

37

 

 

 

35

 

 

 

68

 

 

 

67

 

General and administrative

 

 

15

 

 

 

14

 

 

 

27

 

 

 

26

 

Total stock-based compensation expense

 

$

103

 

 

$

93

 

 

$

188

 

 

$

180

 

As of October 25, 2024, total unrecognized compensation expense related to equity awards was $764 million, which is expected to be recognized on a straight-line basis over a weighted-average remaining service period of 2.2 years.

Stock Repurchase Program

In the first quarter of fiscal 2025, our Board of Directors authorized the repurchase of an additional $1.0 billion of our common stock. As of October 25, 2024, our Board of Directors has authorized cumulative repurchases of up to $17.1 billion of our common stock under our stock repurchase program. Under this program, we may purchase shares of our outstanding common stock through solicited or unsolicited transactions in the open market, in privately negotiated transactions, through accelerated share repurchase programs, pursuant to a Rule 10b5-1 plan or in such other manner as deemed appropriate by our management. The stock repurchase program may be suspended or discontinued at any time.

The following table summarizes activity related to the stock repurchase program for the six months ended October 25, 2024 (in millions, except for per share amounts):

Number of shares repurchased

 

 

5.8

 

Average price per share

 

$

121.58

 

Stock repurchases allocated to additional paid-in capital

 

$

28

 

Stock repurchases allocated to retained earnings

 

$

672

 

Remaining authorization at end of period

 

$

802

 

Since the May 13, 2003 inception of our stock repurchase program through October 25, 2024, we repurchased a total of 377 million shares of our common stock at an average price of $43.25 per share, for an aggregate purchase price of $16.3 billion.

Dividends

The following is a summary of our activities related to dividends on our common stock (in millions, except per share amounts):

 

 

 

Six Months Ended

 

 

 

October 25,
 2024

 

 

October 27,
2023

 

Dividends per share declared

 

$

1.04

 

 

$

1.00

 

Dividend payments allocated to additional paid-in capital

 

$

130

 

 

$

171

 

Dividend payments allocated to retained earnings

 

$

83

 

 

$

38

 

On November 19, 2024, we declared a cash dividend of $0.52 per share of common stock, payable on January 22, 2025 to holders of record as of the close of business on January 3, 2025. The timing and amount of future dividends will depend on market conditions, corporate business and financial considerations and regulatory requirements. All dividends declared have been determined by us to be legally authorized under the laws of the state in which we are incorporated.

 

Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) (AOCI) by component, net of tax, are summarized below (in millions):

 

 

 

Foreign
Currency
Translation
Adjustments

 

 

Defined
Benefit
Obligation
Adjustments

 

 

Unrealized
Gains
(Losses) on
Available-
for-Sale
Securities

 

 

Unrealized
Gains
(Losses) on
Derivative
Instruments

 

 

Total

 

Balance as of April 26, 2024

 

$

(53

)

 

$

(7

)

 

$

 

 

$

1

 

 

$

(59

)

Other comprehensive income (loss), net of tax

 

 

4

 

 

 

 

 

 

1

 

 

 

(3

)

 

 

2

 

Amounts reclassified from AOCI, net of tax

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

2

 

Total other comprehensive income (loss)

 

 

4

 

 

 

 

 

 

1

 

 

 

(1

)

 

 

4

 

Balance as of October 25, 2024

 

$

(49

)

 

$

(7

)

 

$

1

 

 

$

 

 

$

(55

)

 

The amounts reclassified out of AOCI are as follows (in millions):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

 

 

October 25,
 2024

 

 

October 27,
2023

 

 

October 25,
 2024

 

 

October 27,
2023

 

 

Statements of
Income Classification

Realized losses (gains) on cash flow hedges

 

$

2

 

 

$

(3

)

 

$

2

 

 

$

(4

)

 

Net revenues

Total reclassifications

 

$

2

 

 

$

(3

)

 

$

2

 

 

$

(4

)